The unprecedented rise in life expectancy has made advances in the understanding of biological hallmarks of aging, at both the molecular and cellular levels, essential. A joint effort between Baylor College of Medicine, Genentech Inc., Stanford University and collaborating institutions has led to the release of the first Aging Fly Cell Atlas (AFCA) as a result of a deep dive analysis of 163 different cell types in Drosophila melanogaster, the common fruit fly. Read More
At the recent International Society for Stem Cell Research meeting, Vita Therapeutics Inc. presented the first preclinical results on VTA-100, a cell therapy consisting of induced pluripotent stem cell (iPSC)-derived satellite cells, for the treatment of limb-girdle muscular dystrophy 2A/R1. Read More
Researchers from Innate Pharma SA recently presented preclinical data for IPH-6501, a novel CD20-targeting tetraspecific antibody-based natural killer (NK)-cell engager therapeutic being developed for the treatment of patients with B-cell non-Hodgkin lymphoma (B-NHL). Read More
Bluerock Therapeutics LP has reported the first in vitro and in vivo results on the company’s new cell therapy DA-02, consisting of human induced pluripotent stem cell (iPSC)-derived dopaminergic neurons. Read More
The Institute for Drug Research has patented pyrrolidine antiviral compounds acting as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors. Read More
Researchers have developed NCP-112 (Novacell Technology Inc.), a novel FPR2-selective synthetic heptameric peptide ligand, and tested it in preclinical models of atopic dermatitis. Read More
Iaso Biotechnology Co. Ltd. has received FDA approval of the company’s IND application for IASO-782 injection for use in U.S. clinical trials for autoimmune hematological disorders, including primary immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (AIHA). Read More
Research at Kumquat Biosciences Inc. has led to the development of Hetero-atom containing compounds described as tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and (PTPN2; TCPTP) inhibitors and reported to be useful for the treatment of cancer. Read More
Recent Kallyope Inc. patents report AMP-activated protein kinase (AMPK) activators potentially useful for the treatment of allergy, cancer, depression, diabetes type 2, nutrition disorders, obesity, psoriasis, inflammatory bowel disease, metabolic syndrome, nonalcoholic steatohepatitis, Alzheimer’s and Parkinson’s disease, among others. Read More
Having caused over 6.2 million deaths globally ongoing, the COVID-19 pandemic since 2020 continues to pose a serious public health challenge. While the SARS-CoV-2 receptors angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 play requisite roles in permitting the initial infection, up to 10 proviral host factors have also been determined to play crucial roles in controlling the viral replication, but most are not pharmacologically targetable. Read More
Geode Therapeutics Inc. and Xtalpi Inc. have jointly developed phosphatidylinositol 3-kinase γ (PI3Kγ) inhibitors reported to be useful for the treatment of cancer. Read More
New isoindolines acting as mismatch repair endonuclease PMS2 inhibitors have been reported in a Neophore Ltd. patent as useful for the treatment of cancer. Read More
TG Immunopharma Co. Ltd. has announced clearance by the FDA for a clinical trial of TGI-6, a bispecific antibody targeting unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, for solid tumors. Read More
